clinically proven solution in combating and significantly reducing both CATHETER —RELATED BLOODSTREAM INFECTIONS (CR-BSI's) and THROMBOTIC CATHETER OCCLUSIONS (BLOOD CLOTS). These two market opportunities represent a $3.5 billion dollar market opportunity in the U.S alone. CR-BSI's and Blood Clots are two